Emirates Anticancer Pharmaceuticals announced the continuation of research and development.

Jan. 11, 2012 - PRLog -- Emirates Anticancer Pharmaceuticals (EAP) announced the continuation of research and development activities on a new group of selective channel destructors of cell membranes for the years 2012 - 2014. The plan allocates for these purposes, 3.65 million USD and allows for the phasing of the development work. In the first phase will be completed development activities on a group of GLUT and SGLT1 / 2 blockers and destructors, in the second phase are expected activities designed to limit an amino acid metabolism and transport of peptides. In this respect, the EAP has been active for five years, an intent of devitalization of cancer cells towards apoptosis has been reported earlier. There is interesting EAP solution, which is not at high dose concentrations of xenobiotics on the extracellular side of the membrane, but the EAP designs and tests the modified polysaccharide sophisticated supramolecular structures that ensure that the effect of drug metabolites are easily transportable outside the body, but also the effect of action will be guaranteed for the effect of targeted therapeutics to cells and tissues.

Representative, Dr. Raffa Sayed, said: "More than six years we have verified some of the hypotheses, we can say that we have carried out research at a basic level, essentially academic. At this stage it should be no longer focus on these areas, we should focus on other activities which in terms of potential applicability of the results offer the best chance to apply, that is the greatest commercial and therapeutic potential. I can now reveal that GLUT2-SGLT2 intra-membrane BGW1114 blocker has extra features and the selected lines of some cancer stem cells, of course, in vitro , we achieve smooth apoptosis. But everything is still at the beginning, so it is not possible to talk about anything other than the great promise. There are mainly prepared to announced two more stages of development and aim for the years 2014 and 2015 is carried out first experiments with targeted transport in vivo. It is known that we have contacted several manufacturers of nano-carriers, because our strategy is to be ready."

In this context, Dr. Sayed also commented announced entry into the consortium Nanobot SIG:

"Yes, in September 2011 we entered into the project consortium Nanobot Research Group and three months later to the Nanobot SIG. We appreciate the cooperation of all stakeholders, especially The Azacycles, which in 2010 introduced in our UAE center two important technologies that they can us move to the next level. Azacycles (http://www.azacycles.com) is very atractive partner for us and also the guarantee that the objectives of the consortium Nanobot SIG will be completely fulfilled."

To earlier announced plans of Emirates Anticancer Pharmaceuticals (http://www.anticancer.ae) of in-membrane nano-hooks, Dr. Sayed said:

"Nano-hooks for cell membranes are our priority for a large production, but are at the stage of the investment when no large-scale developments are required. Therefore, moving attention to the activities which we feel a greater urgency on investment and where possible return of investment is higher, especially crafted with the cooperation with similar stakeholders. Nano-hooks we presented at a nanotechnology conference in Dubai, the whole attention focused on our technology has been very pleasing. We expect the second half of 2013 the introduction on the market."

Emirates Anticancer Pharmaceuticals (http://www.anticancer.ae/promo-eap.pdf) are undoubtedly among the most promising biotechnology companies engaged in research and development of new forms of drugs with minimal toxicity in the human body.